Elder hikes stake in Bulgarian arm
This article was originally published in Scrip
Executive Summary
Elder Pharmaceuticals has increased its holding in its Bulgarian subsidiary, Elder Biomeda AD, to 61% from 51%. The company expects to use its Bulgarian arm as a "strategic gateway" to the EU and the CIS region. Biomeda's original owners will continue to hold the remaining 39% stake in the subsidiary.